Should mFOLFIRINOX Be Standard of Care in Adjuvant Tx of Pancreatic Cancer?

Compared with gemcitabine, mFOLFIRINOX improved outcomes for all endpoints when used in the adjuvant setting.

Source: CancerNetwork - June 14, 2018 Category: Cancer & Oncology Authors: Cancer Network Editors Source Type: news